Akums Drugs and Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 5/6
Akums Drugs and Pharmaceuticals has a total shareholder equity of ₹7.2B and total debt of ₹4.9B, which brings its debt-to-equity ratio to 68.2%. Its total assets and total liabilities are ₹35.2B and ₹28.0B respectively. Akums Drugs and Pharmaceuticals's EBIT is ₹3.6B making its interest coverage ratio 9.4. It has cash and short-term investments of ₹2.8B.
Key information
68.2%
Debt to equity ratio
₹4.92b
Debt
Interest coverage ratio | 9.4x |
Cash | ₹2.77b |
Equity | ₹7.20b |
Total liabilities | ₹27.96b |
Total assets | ₹35.16b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 544222's short term assets (₹19.4B) exceed its short term liabilities (₹12.1B).
Long Term Liabilities: 544222's short term assets (₹19.4B) exceed its long term liabilities (₹15.9B).
Debt to Equity History and Analysis
Debt Level: 544222's net debt to equity ratio (29.8%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if 544222's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable 544222 has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: 544222 is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 56.4% per year.